Tibet Rhodiola Pharmaceutical Holding

Tibet Rhodiola Pharmaceutical Holding EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Tibet Rhodiola Pharmaceutical Holding (600211.SS) as of Oct 18, 2026 is 924.70 M CNY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 1.20 B CNY — a change of -22.66% (lower).

EBITDA

924.70 MCNY

YoY

-22.66%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Tibet Rhodiola Pharmaceutical Holding is 2025 924.70 M CNY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Tibet Rhodiola Pharmaceutical Holding was 2024 1.20 B CNY. It decreases by -22.66% lower compared to the previous year.

The Tibet Rhodiola Pharmaceutical Holding EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
248.25 M CNY
Jan 1, 2019
358.02 M CNY
Jan 1, 2020
478.52 M CNY
Jan 1, 2021
271.33 M CNY
Jan 1, 2022
494.86 M CNY
Jan 1, 2023
925.08 M CNY
Jan 1, 2024
1.20 B CNY
Jan 1, 2025
924.70 M CNY
The Tibet Rhodiola Pharmaceutical Holding EBITDA history
YEAREBITDAYoY
924.70 MCNY-22.66%
1.20 BCNY+29.24%
925.08 MCNY+86.94%
494.86 MCNY+82.38%
271.33 MCNY-43.30%
478.52 MCNY+33.66%
358.02 MCNY+44.22%
248.25 MCNY+14.41%
216.98 MCNY+7.26%
202.28 MCNY+77.68%
113.85 MCNY+253.11%
32.24 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Tibet Rhodiola Pharmaceutical Holding Stock analysis

What does Tibet Rhodiola Pharmaceutical Holding do? Tibet Rhodiola Pharmaceutical Holding Co, listed on the Shanghai Stock Exchange under ticker 600211.SS, operates as a pharmaceutical company based in Lhasa, China. The company's ISIN is CNE000000ZW7. Founded through an IPO on July 21, 1999, it specializes in the manufacture and wholesale of pharmaceutical products. Its headquarters are located in Lhasa, Xizang, and it employs 615 full-time staff. The firm distributes proprietary drug products and processes pharmaceuticals, conducting business primarily across South China, North China, East China, Central China, and overseas markets. The company's website is http://www.xzyy.cn. It does not provide details on specific products, acquisitions, or financial figures beyond the IPO date and employee count. The company focuses on pharmaceutical manufacturing and distribution within its operational regions, with no additional information provided on its product lines or market share. Tibet Rhodiola Pharmaceutical Holding is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tibet Rhodiola Pharmaceutical Holding stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Tibet Rhodiola Pharmaceutical Holding is 924.70 M CNY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Tibet Rhodiola Pharmaceutical Holding changed from 1.20 B CNY to 924.70 M CNY, representing a -22.66% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Tibet Rhodiola Pharmaceutical Holding since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Tibet Rhodiola Pharmaceutical Holding historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Tibet Rhodiola Pharmaceutical Holding

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Tibet Rhodiola Pharmaceutical Holding